Human Papilloma Virus
134
20
31
66
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
23 trials with published results (17%)
Research Maturity
66 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.0%
4 terminated out of 134 trials
94.3%
+7.7% vs benchmark
10%
13 trials in Phase 3/4
35%
23 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 66 completed trials
Clinical Trials (134)
Developing and Implementing HPV SCREENED
PopSci CHW4CervixHealth
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Hashtag HPV: HPV Vaccine Twitter Education Program
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Merck IIT: RRP Pembro and Lenvatinib
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks
Impact of Financial Incentives
Blood Biomarkers Based Screening for HPV-driven OPC
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
A Proximity-incentive Strategy for Cervical Cancer Screening
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Impact of Standing Orders Optimization
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department